Download your copy of the interactive treatment algorithm
Access this comprehensive, interactive algorithm developed by Idorsia Pharmaceuticals Ltd, in consultation with the authors, utilising the BMC Primary Care publication “Assessment and management of chronic insomnia disorder: an algorithm for primary care physicians” Selsick et al. BMC Primary Care (2024) 25:138.5
This guide includes:
- Patient assessment steps to diagnose chronic insomnia
- Therapeutic recommendations tailored to patient-specific needs
- Treatment options focused on tailored prescription pathways
- Key considerations for patient management
Promotional material from Idorsia Pharmaceuticals UK Ltd.
References
1 – QUVIVIQ™▼ (daridorexant) Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
2 – Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708.
3 – NICE Clinical Knowledge Summary (CKS) Insomnia: Scenario: Managing long-term insomnia (more than 3 months duration). Available at: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/. Updated May 2025. Accessed July 2025.
4 – Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139.
5 – Selsick et al. BMC Primary Care (2024) 25:138.
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.
